NYMX - farmaco cancro prostata

Mr China Investiment

Nuovo Utente
Registrato
19/5/00
Messaggi
22.068
Punti reazioni
913
NYMX - farmaco prostata

Dutton Associates Announces Investment Opinion: Nymox Pharmaceutical Strong Speculative Buy Rating in Update Coverage by Dutton Associates
Wednesday March 15, 12:00 pm ET


EL DORADO HILLS, Calif.--(BUSINESS WIRE)--March 15, 2006--Dutton Associates updates its coverage of Nymox Pharmaceutical (Nasdaq:NYMX - News) maintaining a Strong Speculative Buy rating and a $6.25 price target. The 8-page report by Dutton senior analyst William Prather R.Ph., M.D., is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.
ADVERTISEMENT


As mentioned in our initial report in November 2005, we believe a major reason to invest in Nymox Pharmaceutical Corporation is related to the potential of the Company's NX-1207 for benign prostatic hyperplasia (BPH). Our monitoring of the clinical development of this compound indicates that the product is on track to enter Phase III clinical trials in latter 2006. In two completed trials in the U.S. to date, the drug has shown highly significant efficacy without significant adverse side effects or safety problems. Additionally, we believe a marketing collaboration for NX-1207 could be announced even before these Phase III trials are initiated. Based on the assumptions that Nymox will announce a marketing partner over the near term and will be in Phase III clinical trials next year at this time, we are maintaining our 12-month price target on the common shares of $6.25 and our rating of Strong Speculative Buy.

About Dutton Associates

Dutton Associates is one of the largest independent investment research firms in the U.S. Its 27 senior analysts are primarily CFAs, and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 120 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.

The cost of enrollment in our one-year continuing research program is US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $43,000 from the Company for 6 Research Reports with coverage commencing on 11/17/2005. We do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.
 
Ultima modifica:
Nymox Reports 2005 Financial Results
Wednesday March 15, 9:00 am ET
Product Sales Increase by 32%


HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--March 15, 2006--Nymox Pharmaceutical Corporation (NASDAQ: NYMX - News) announced today its financial results for the year ended December 31, 2005. Product sales increased by 32% and amounted to $424,506 for 2005, compared to $321,895 for 2004. Nymox currently has $11.9 million in financing available from its most recent October 21, 2005 financing. Nymox reported a net loss of $3,584,528, or $0.14 per share, compared to $3,745,625, or $0.15 per share for 2004. The weighted, diluted average number of common shares at December 31, 2005 was 26,103,704, compared to 25,103,252 at December 31, 2004.
ADVERTISEMENT


"The Company had a highly productive year in which many solid milestones were made, while our burn rate was again minimal by industry standards", said Paul Averback, CEO and President of Nymox.

Nymox Pharmaceutical Corporation is a biopharmaceutical company with three unique proprietary products on the market, and a significant R&D pipeline of drug products in development. Nymox is developing NX-1207, a novel treatment for benign prostatic hyperplasia. NX-1207 has shown statistically significant positive results in Phase 1 and 2 clinical trials in the U.S. and is currently in pivotal late stage Phase 2 human testing in the US. Nymox has U.S. and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company is developing a new treatment for E. coli O157:H7 contamination in food products. Nymox has NXD-2858 and NXD-9062 which are under development as drug treatments aimed at the causes of Alzheimer's disease, and has several other drug candidates in development. Nymox developed and is currently offering its AlzheimAlert(TM) test, a nationally certified clinical reference laboratory urinary test that is the world's only accurate, non-invasive aid in the diagnosis of Alzheimer's disease. The AlzheimAlert(TM) test is certified with a CE Mark, making the device eligible for sale in the European Union. Nymox has signed distribution deals for AlzheimAlert(TM) with several companies in Europe. Nymox also developed and markets NicAlert(TM) and TobacAlert(TM); tests that use urine or saliva to detect use of and exposure to tobacco products. NicAlert(TM) has received clearance from the U.S. Food and Drug Administration (FDA) and is also certified with a CE Mark in Europe. TobacAlert(TM) is the first test of its kind to accurately measure second hand smoke exposure in individuals.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
 
minkia china entri ed esci ma che bordello è questo ehehehheheheh dai l'indirizzo a zantrax cosi si rilassa
 
Mr China Investiment ha scritto:
Ciao Gian!

entrato pur ein VPHM a 9.85 :D

uscito da PRGX a 0.60 :D :D

Ciao mio caro,
oggi ho già fatto abbastanza shopping dentro AMPX e PFSW
 
Adsx ha scritto:
Ciao mio caro,
oggi ho già fatto abbastanza shopping dentro AMPX e PFSW


su NYMX ora ci andrei cauto....

guarda su YAHOO FORUM...dopo averla super pompata la stanno da due tre minuti "bruciando"

mi metto vicino ai 5 :D
 
Mr China Investiment ha scritto:
su NYMX ora ci andrei cauto....

guarda su YAHOO FORUM...dopo averla super pompata la stanno da due tre minuti "bruciando"

mi metto vicino ai 5 :D


mi dai il link :)
 
Mr China Investiment ha scritto:
su NYMX ora ci andrei cauto....

guarda su YAHOO FORUM...dopo averla super pompata la stanno da due tre minuti "bruciando"

mi metto vicino ai 5 :D

Io nn mi metto proprio x adesso. PASSO, alla prossima mano.
 
Indietro